Publications by authors named "J M Vose"
Article Synopsis
- High-grade B-cell lymphoma not otherwise specified (HGBCL, NOS) shares similarities with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), which complicates its diagnosis and treatment.
- A study on a cohort of 55 patients revealed that about 60% of HGBCL, NOS cases don't express the BL gene signature and instead display characteristics aligned with DLBCL, while showing significant genetic diversity and changes in critical regulatory genes.
- Pediatric HGBCL, NOS cases exhibited gene expressions typical of GCB-DLBCL and also showed key mutations seen in pediatric BL; the research highlighted PIM1 mutations in adults as a potential target for new therapies.
Article Synopsis
- There is limited knowledge about the risk of central nervous system (CNS) involvement in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS), prompting a study that assessed baseline CNS involvement, recurrence rates, and management strategies in patients treated from 2016 to 2021.
- In the study of 160 adults, 7% exhibited baseline CNS involvement, which was linked to MYC rearrangement and certain sites of involvement, but did not significantly impact overall survival outcomes compared to those without CNS involvement.
- The risk of CNS recurrence within three years was found to be 11%, with patients showing initial CNS involvement facing a much higher risk (48.5%), while various other factors such as blood involvement and
Purpose: Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy.
Methods: We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.
Purpose: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell (PBSC) transplantation for non-Hodgkin lymphoma (NHL). Previous studies report an association between clonal hematopoiesis (CH) in PBSC and risk of t-MN, but small samples precluded examination of risk within specific subpopulations.
Methods: Targeted DNA sequencing was performed to identify CH mutations in PBSC from a retrospective cohort of 984 patients with NHL (median age at transplant, 57 years; range, 18-78).
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive lymphoma characterized by constitutive NF-κB activation, but whether miR-17∼92 contributes to this activation remains unclear. Herein, we sought to evaluate the role of miR-17∼92 in the process of NF-κB activation in ABC-DLBCL. We found that the expression of miR-17∼92 primary transcript was positively correlated with NF-κB activity, miR-17∼92 activated the NF-κB signaling in ABC-DLBCL, and its over-expression promoted ABC-DLBCL cell growth, accelerated cell G1 to S phase transition and enhanced cell resistance to NF-κB inhibitor.
View Article and Find Full Text PDF